- 67 Downloads
Gatifloxacin (Tequin®) is an 8-methoxy fluoroquinolone approved in the US for use in the treatment of community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), acute sinusitis, uncomplicated and complicated urinary tract infections (UTIs), pyelonephritis, gonorrhoea and uncomplicated skin and skin structure infections.
Gatifloxacin has a broad spectrum of antibacterial activity in vitro and good clinical and bacteriological efficacy in patients with indicated infections following once-daily administration by the intravenous or oral routes. It is generally well tolerated; the most common adverse events are associated with the gastrointestinal tract and CNS. Recent approvals for the use of gatifloxacin in the treatment of CAP due to multidrug-resistant Streptococcus pneumoniae (MDRSP) and in uncomplicated skin and skin structure infections extend the role of this drug in the treatment of bacterial infections in the US.
Pharmacological Properties and Antimicrobial Activity
Gatifloxacin, an 8-methoxy fluoroquinolone with a 3-methylpiperazinyl substitution at C-7, inhibits bacterial DNA gyrase and topoisomerase IV. It has a broad spectrum of activity against Gram-positive and Gram-negative aerobic bacteria and atypical bacteria, but has limited activity against most anaerobes.
Gatifloxacin is active against S. pneumoniae, including penicillin-resistant strains, and oxacillin-susceptible Staphylococcus aureus, with minimum concentrations required to inhibit 90% of strains (MIC90) of ≤0.5 mg/L. The percentage of Gram-positive isolates susceptible to gatifloxacin is similar to those of gemifloxacin, moxifloxacin and levofloxacin, and higher than that of ciproflox-acin. Gatifloxacin activity against enterococci is very limited.
Haemophilus influenzae and Moraxella catarrhalis are susceptible to gatifloxacin (both MIC90 ≤0.03 mg/L), and gatifloxacin is active against Neisseria gonorrhoeae, including ciprofloxacin-resistant and β-lactamase-positive strains (MIC90 0.016–0.06 mg/L). Gatifloxacin has good activity against Enterobacter spp. (MIC90 0.5–1 mg/L), Klebsiella spp. (MIC90 0.25–2 mg/L) and most isolates of Escherichia coli (MIC90 0.06 to >4 mg/L). Activity against Proteus mirabilis is variable (MIC90 2–16 mg/L). Like most other fluoroquinolones, gatifloxacin has poor activity against Pseudomonas aeruginosa (in North America, 61–67% of isolates were susceptible to gatifloxacin). The atypical respiratory organisms Chlamydophilia (Chlamydia) pneumoniae, Mycoplasma pneumoniae and Legionella spp. are also susceptible to gatifloxacin (MIC90 0.03–0.5 mg/L).
Surveillance programmes in the US have found that bacterial resistance to gatifloxacin among respiratory pathogens, including S. pneumoniae, is low (≤1%); in vitro studies suggest that gatifloxacin has a lower potential to select for mutants than older fluoroquinolones. The activity of gatifloxacin is concentration-dependent, and as with other fluoroquinolones, area under the concentration-time curve (AUC): MIC ratios of ≈30 or greater and >100–125 are considered predictors of clinical and bacteriological efficacy against S. pneumoniae and Gram-negative bacteria, respectively. In patients receiving oral gatifloxacin 400mg once daily, the probability of achieving an AUC: MIC ratio ≥30 for S. pneumoniae is 97.6%. Gatifloxacin shows a post-antibiotic effect against a range of bacteria.
The pharmacokinetic profile of gatifloxacin is similar after oral or intravenous administration and steady state is achieved after 3 days. Gatifloxacin concentrations achieved in most target tissues and fluids generally exceed the MIC90 values for common pathogens at these sites. It is primarily excreted as unchanged drug through the kidneys, and dosage adjustments are recommended for patients with creatinine clearance <2.4 L/h (<40 mL/min). Coadministration of iron, zinc, magnesium or aluminium (but not calcium) salts significantly reduces the absorption of orally-administered gatifloxacin. Gatifloxacin increases plasma digoxin concentrations in some patients, and those receiving both drugs should be monitored for signs of digoxin toxicity. Gatifloxacin does not inhibit cytochrome P450 (CYP) enzymes and is unlikely to affect CYP-dependent metabolism of drugs.
A number of randomised, comparative trials have shown that once-daily gatifloxacin at US-approved dosages was as effective as comparator agents in the treatment of adults with a range of bacterial infections affecting the respiratory tract, genitourinary tract and skin or skin structures. In most studies, the primary endpoint was the clinical cure rate at the test-of-cure visit; for genitourinary tract infections, it was the bacteriological response.
In patients with CAP, intravenous and/or oral gatifloxacin 400mg once daily for 7–14 days achieved a clinical cure rate similar to that seen with comparators, including levofloxacin, clarithromycin and ceftriaxone/clarithromycin (95–97% vs 91–94%). Bacteriological eradication rates were 97–98% in gatifloxacin recipients and 92–93% in patients receiving comparator drugs. Gatifloxacin achieved 100% clinical and bacteriological success rates in 27 patients with CAP caused by MDRSP, based on data largely from post-marketing studies.
Oral gatifloxacin 400mg once daily for 5 days was as effective as standard 7- to 10-day regimens of gatifloxacin, clarithromycin or amoxicillin/clavulanic acid in patients with AECB. Clinical cure and bacteriological eradication rates were 79–89% and 87–98% with short-course gatifloxacin compared with 82–89% and 79–98% with the comparator regimens.
In patients with acute uncomplicated maxillary sinusitis of presumed bacterial origin, oral gatifloxacin 400mg once daily for 10 days achieved clinical cure rates similar to those with clarithromycin (14 days) or amoxicillin/clavulanic acid (10 days) [80–93% vs 72–90%]. Bacteriological efficacy was not assessed.
Treatment with either a single oral dose of gatifloxacin 400mg or gatifloxacin 200mg once daily for 3 days achieved similar bacteriological response rates to those seen with ciprofloxacin 250mg twice daily for 3 days in patients with acute uncomplicated UTIs. Clinical response rates were also equivalent to those with ciprofloxacin for the gatifloxacin 200mg regimen and (in one of two trials) single-dose gatifloxacin 400mg. Bacteriological and clinical response rates were also similar between gatifloxacin (400mg once daily) and ciprofloxacin (500mg twice daily), in patients with complicated UTIs or pyelonephritis treated for 7–10 days. Overall, for patients with UTIs including pyelonephritis, per-patient bacteriological response rates were 81–95% for gatifloxacin compared with 82–89% for ciprofloxacin. Clinical response rates were 81–100% versus 85–95%.
A single oral dose of gatifloxacin 400mg was as effective as a single dose of ofloxacin 400mg in patients with uncomplicated gonococcal infection. The per-patient bacteriological eradication rate was ≥99% in both groups. Symptoms resolved in 96% of men in both groups and 72% vs 78% of female gatifloxacin or ofloxacin recipients.
In patients with uncomplicated skin or skin structure infections, gatifloxacin 400mg once daily for 7–10 days achieved similar rates of clinical cure (91% vs 84%) and bacteriological eradication (92% vs 92%) to those seen with levoflox-acin 500mg once daily.
Gatifloxacin is generally well tolerated, with most adverse events being mild in severity. In pooled data from worldwide trials, the most common events related to gatifloxacin were generally associated with the gastrointestinal system (e.g. nausea, diarrhoea) or CNS (e.g. headache, dizziness). In a large, noncomparative post-marketing study, the incidence of gatifloxacin-related adverse events in patients aged ≥80 years was 18% compared with 13% in patients aged ≤79 years.
Disturbances of glucose homeostasis can occur in patients treated with gatifloxacin, particularly in those with diabetes mellitus; severe, sometimes life-threatening, hyper- and hypoglycaemic events have been reported. For example, five serious drug-related adverse events related to glucose homeostasis were reported in the post-marketing study (among >15 000 patients). Occasional cases of torsades de pointes have been reported with gatifloxacin. Gatifloxacin is not associated with phototoxicity, and tendon ruptures and hepatitis occur rarely. 1 The use of trade names is for product identification purposes only and does not imply endorsement.
KeywordsLevofloxacin Moxifloxacin Gatifloxacin Clinical Cure Rate Gemifloxacin
- 3.Bristol-Myers Squibb Company. Princeton, New Jersey, USA. Tequin® (gatifloxacin) prescribing information. 2004 Nov [online]. Available from URL: http://www.tequin.com [Accessed 2004 Nov 30]
- 4.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement. Wayne (PA): Clinical and Laboratory Standards Institute, 2005 Jan. Report no: M100-S15 (M7)Google Scholar
- 5.Sahm DF, Weaver MK, Flamm RK, et al. Rates of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States: results from the TRUST 7 (2002–2003) Surveillance Study [abstract no. 201 plus poster]. 41st Annual Meeting of the Infectious Diseases Society of America; 2003 Oct 9–12; San Diego, 63Google Scholar
- 8.Hoban DJ, Biedenbach DJ, Mutnick AH, et al. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn Microbiol Infect Dis 2003 Apr; 45(4): 279–85PubMedCrossRefGoogle Scholar
- 10.Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis 2001 May 15; 32 Suppl. 2: S81–93PubMedCrossRefGoogle Scholar
- 16.Pfaller MA, Ehrhardt AF, Jones RN. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the Respiratory Surveillance Program study: microbiology from the medical office practice environment. Am J Med 2001 Dec 17; 111(9A): 4S–12SPubMedCrossRefGoogle Scholar
- 17.Johnson DM, Sader HS, Fritsche TR, et al. Susceptibility trends of Haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2003; 47: 373–6PubMedCrossRefGoogle Scholar
- 19.Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47(6): 1875–81PubMedCrossRefGoogle Scholar
- 20.Rennie RP, Jones RN, Mutnick AH. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 2003; 45(4): 287–93PubMedCrossRefGoogle Scholar
- 21.Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis 2001 May 15; 32 Suppl. 2: S114–32PubMedCrossRefGoogle Scholar
- 22.Mathai D, Lewis MT, Kugler KC, et al. Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I-results from the SENTRY Antimicrobial Surveillance Program (North America, 1998). Diagn Microbiol Infect Dis 2001 Feb; 39(2): 105–16PubMedCrossRefGoogle Scholar
- 23.Mathai D, Jones RN, Pfaller MA, et al. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America). Diagn Microbiol Infect Dis 2001 Jul; 40(3): 129–36PubMedCrossRefGoogle Scholar
- 24.Thornsberry C, Karlowsky JA, Weaver MK, et al. Current view of antimicrobial susceptibility among common Gram-Negative pathogens: 2003 TRUST Surveillance Study [abstract no. 222 plus poster]. 41st Annual Meeting of the Infectious Diseases Society of America; 2003 Oct 9–12; San Diego, 68Google Scholar
- 34.Meagher AK, Craing WA, Jones RN, et al. Monte Carlo simulation (MCS) to estimate in vitro susceptibility breakpoints (BPs) for moxifloxacin (M), gatifloxacin (G) and levifloxacin (L) against Staphyiococcus aureus (SA) [abstract no. A-136]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC, 11Google Scholar
- 37.Blondeau JM, Borsos S, Hesje C, et al. The killing of multidrug resistant Streptococcus pneumoniae (MDRSP) by gatifloxacin (GA), gemifloxacin (GM), levofloxacin (Lfx) and moxifloxacin (Mfx) over a range of bacterial inoculums using 2 different drug concentrations [abstract no. 629 plus poster]. World conference on magic bullets: celebrating Paul Ehrlich’s 150th birthday; 2004 Sep 9–11; NürnbergGoogle Scholar
- 42.Boy D, Well M, Kinzig-Schippers M, et al. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. Int J Antimicrob Agents 2004 Mar; 23 Suppl. 1: S6–S16PubMedCrossRefGoogle Scholar
- 51.Pfaller MA, Jones RN. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections. Diagn Microbiol Infect Dis 2002 Sep; 44: 77–84PubMedCrossRefGoogle Scholar
- 57.Powis J, Fuller J, Vanderkooi O, et al. Lower levels of in vitro nonsusceptibility to moxifloxacin compared with other fluoroquinolones in Canadian clinical isolates of Streptococcus pneumoniae [abstract no. P1702]. Clin Microbiol Infect 2004 May; 10 Suppl. 3: 482Google Scholar
- 58.Smith HJ, Nichol KA, Palatnick L, et al. In vitro activity of ABT-492 against ciprofloxacin-resistant Streptococcus pneumoniae (CR SPN) compared to eight other drugs [abstract no. F549 plus poster]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27–30; San Diego, 184Google Scholar
- 61.Smith HJ, Walters M, Hisanaga T, et al. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob Agents Chemother 2004 Oct; 48(10): 3954–8PubMedCrossRefGoogle Scholar
- 62.Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella cat-arrhalis in the United States: results from the TRUST Surveillance program, 1999–2000. Clin Infect Dis 2002; 34 Suppl. 1: S4–16PubMedCrossRefGoogle Scholar
- 63.Selman LJ, Mayfield DC, Thornsberry C, et al. Changes in single- and multiple-drug resistance among Streptococcus pneumoniae over three years (1997–2000) [abstract no. 1789]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto, 108Google Scholar
- 64.Metzler K, Hansen GM, Hedlin P, et al. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents 2004 Aug; 24(2): 161–7PubMedCrossRefGoogle Scholar
- 66.Thornsberry C, Sahm DF, Weaver MK, et al. Antimicrobial susceptibilities of common pathogens causing nosocomial pneumonia: 2001–2003 TRUST surveillance [abstract no. E-2187 plus poster]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago, 216Google Scholar
- 73.Jones RN, Rubino CM, Bhavnani SM, et al. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother 2003 Jan; 47(1): 292–6PubMedCrossRefGoogle Scholar
- 81.Gajjar DA, LaCreta FP, Kollia GD, et al. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy 2000 Jun; 20 (6 Pt 2): 76S–86SPubMedCrossRefGoogle Scholar
- 93.Baba S, Suzuki K, Ichikawa G, et al. Pharmacokinetic and clinical studies of gatifloxacin on otorhinolaryngological infections [in Japanese]. Jpn J Chemother 1999 Oct; 47(10): 632–48Google Scholar
- 94.Honeybourne D, Wise R, Stahlberg H-J, et al. Tissue penetration of gatifloxacin into bronchial mucosa (BM), epithelial lining fluid (ELF) and alveolar macrophages (AMS) after administration of a single 400mg oral dose [abstract no. 248]. Antiinfect Drugs Chemother 2000; 17(1): 87Google Scholar
- 95.Saito A, Nakayama I, Ohmichi M, et al. Early phase II clinical study of gatifloxacin, an oral new quinolone, for infections in the field of internal medicine [in Japanese]. Jpn J Chemother 1999 Sep; 47 Suppl. 2: 260–76Google Scholar
- 96.Saito A, Ohmichi M, Arakawa M, et al. Late phase-II clinical study of gatifloxacin, an oral new quinolone, in respiratory tract infections [in Japanese]. Jpn J Chemother 1999 Sep; 47 Suppl. 2: 277–91Google Scholar
- 97.Watanabe H, Masaki H, Watanabe K, et al. Clinical evaluation of gatifloxacin, a new fluoroquinolone, in chronic respiratory tract infections: it’s penetration into sputum and bactericidal effect [in Japanese]. Jpn J Chemother 1999 Oct; 47(10): 623–31Google Scholar
- 98.Matsuda S, Ando S, Chimura T, et al. Genital tissue penetration and clinical evaluation of gatifloxacin, a new fluoroquinolone, in obstetrics and gynecology [in Japanese]. Jpn J Chemother 1999 Dec; 47(12): 829–42Google Scholar
- 99.Tsugawa M, Monden K, Kumon H, et al. Clinical study of gatifloxacin in prostatitis [in Japanese]. Jpn J Chemother 1999 Dec; 47(12): 843–51Google Scholar
- 100.Naber CK, Steghafner M, Kinzig-Schippers M, et al. Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers. Antimicrob Agents Chemother 2001 Jan; 45(1): 293–7PubMedCrossRefGoogle Scholar
- 101.Stahlberg HJ, Gohler K, Leclerc V, et al. The effect of varying degrees of renal impairment on the pharmacokinetics and safety of gatifloxacin [abstract no. 195]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco, 11Google Scholar
- 102.Kawada Y, Kanimoto Y, Takahashi Y, et al. Pharmacokinetics of gatifloxacin in patients with impaired renal function [in Japanese]. Jpn J Chemother 1999 Sep; 47 Suppl. 2: 238–47Google Scholar
- 103.Aoki N, Shiba K. Pharmacokinetics of gatifloxacin, a new quinolone, in elderly patients [in Japanese]. Jpn J Chemother 1999 Sep; 47 Suppl. 2: 230–7Google Scholar
- 105.Grasela T, Cirincione B, Christofalo B, et al. Population pharmacokinetics (PPK) of gatifloxacin in adults with acute bacterial exacerbation of chronic bronchitis (ABECB) [abstract no. A-28]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego, 9Google Scholar
- 106.Olsen SJ, Uderman HD. Pharmacokinetics (PK) of concomitantly administered gatifloxacin and digoxin [abstract no. 199]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco, 12Google Scholar
- 107.Kays MB, Overholser BR, Lagvankar S, et al. Effect of Ensure on the oral bioavailability of gatifloxacin [abstract no. A-1626]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago, 39Google Scholar
- 109.Ramirez JA, Nguyen T-H, Tellier G, et al. Treating community-acquired pneumonia with once-daily gatilfoxacin vs twice-daily clarithromycin. J Respir Dis 1999 Nov; 20 (11 Suppl.): S40–8Google Scholar
- 111.Naber KG, Allin DM, Clarysse L, et al. Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. Int J Antimicrob Agents 2004 Jun; 23(6): 596–605PubMedCrossRefGoogle Scholar
- 115.Cox CC, Marbury TC, Pittman WG, et al. A multicenter comparison of gatifloxacin (GAT) 400mg QD vs. ciprofloxacin (CIP) 500mg BID in the treatment of complicated urinary tract infection (UTI) and pyelonephritis [abstract no. 612]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco, 665Google Scholar
- 116.Fogarty C, Dowell ME, Ellison WT, et al. Treating community-acquired pneumonia in hospitalized patients: gatifloxacin vs ceftriaxone/clarithromycin. J Respir Dis 1999 Nov; 20 (11 Suppl.): S60–9Google Scholar
- 117.Sullivan JG, McElroy AD, Honsinger RW, et al. Treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin. J Respir Dis 1999 Nov; 20 (11 Suppl.): S49–59Google Scholar
- 119.Fogarty C, McAdoo MA, Zorba Paster R, et al. Gatifloxacin vs clarithromycin in the management of acute sinusitis. J Respir Dis 1999 Nov; 20 (11 Suppl.): S17–22Google Scholar
- 121.Richard GA, Mathew CP, Kirstein JM, et al. Single-dose fluoro-quinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. Urology 2002 Mar; 59(3): 334–9PubMedCrossRefGoogle Scholar
- 125.Von Seggern K., Russo R, Wilder MA. A novel approach to postmarketing surveillance: the Tequin Clinical Experience Study [poster no. 2216]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San FranciscoGoogle Scholar
- 127.Breen J, Skuba K, Grasela D. Safety and tolerability of gatifloxacin, an advanced-generation, 8-methoxy fluoroquinolone. J Respir Dis 1999 Nov; 20 (11 Suppl.): S70–6Google Scholar
- 132.Tailor SAN, Simor AE, Cornish W, et al. Analysis of spontaneous reports of hypoglycemia and hyperglycemia associated with marketed systemic fluoroquinolones made to the Canadian Adverse Drag Reaction Monitoring Program. Can J Hosp Pharm 2004 Feb; 57(1): 12–7Google Scholar
- 140.American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730–54Google Scholar
- 141.Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004; 130 (1 Suppl.): 1–45Google Scholar
- 142.Brook I, Gooch WM, Reiner SA, et al. Medical management of acute bacterial sinusitis: recommendations of a clinical advisory committee on pediatric and adult sinusitis. Ann Otol Rhinol Laryngol 2000; 109: 1–20Google Scholar
- 146.Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines 2002. MMWR 2002 May 10; 51 (No. RR-6) [online]. Available from URL: www.cdc.gov/ mmwr [Accessed 2005 Jan 10]Google Scholar
- 148.Bayer Pharmaceuticals Corporation. Avelox® (moxifloxacin hydrochloride) tablets, Avelox® I.V. (moxifloxacin hydrochloride in sodium chloride injection) prescribing information. 2004 Oct [online]. Available from URL: http://www.aveloxusa.com [Accessed 2005 Jan 17]
- 149.Oscient Pharmaceuticals. Factive® (gemifloxacin mesylate) tablets prescribing information. 2004 Feb [online]. Available from URL: http://www.oscient.com [Accessed 2005 Jan 17]